CN103298345B - 组合 - Google Patents
组合 Download PDFInfo
- Publication number
- CN103298345B CN103298345B CN201280004830.0A CN201280004830A CN103298345B CN 103298345 B CN103298345 B CN 103298345B CN 201280004830 A CN201280004830 A CN 201280004830A CN 103298345 B CN103298345 B CN 103298345B
- Authority
- CN
- China
- Prior art keywords
- methyl
- chloro
- compound
- administered
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- GXJABQQUPOEUTA-RDJZCZTQSA-N CC(C)C[C@@H](B(O)O)NC([C@H](Cc1ccccc1)NC(c1nccnc1)=O)=O Chemical compound CC(C)C[C@@H](B(O)O)NC([C@H](Cc1ccccc1)NC(c1nccnc1)=O)=O GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- LNIFEKHXOSXTPP-GCRRARIESA-N CN/C(/c(cc(C(N[C@@H](Cc1cc(F)ccc1)CN)=O)[s]1)c1Cl)=C(\C=N)/Cl Chemical compound CN/C(/c(cc(C(N[C@@H](Cc1cc(F)ccc1)CN)=O)[s]1)c1Cl)=C(\C=N)/Cl LNIFEKHXOSXTPP-GCRRARIESA-N 0.000 description 1
- ZEESWPRDQGWOMU-AWEZNQCLSA-N Cc([s]c(C(N[C@@H](Cc1cccc(F)c1)CN)=O)c1)c1-c([n](C)nc1)c1Cl Chemical compound Cc([s]c(C(N[C@@H](Cc1cccc(F)c1)CN)=O)c1)c1-c([n](C)nc1)c1Cl ZEESWPRDQGWOMU-AWEZNQCLSA-N 0.000 description 1
- ULDXWLCXEDXJGE-UHFFFAOYSA-N NC1(CCC1)c(cc1)ccc1-c(c(-c1ccccc1)c1)nc(C=CN23)c1C2=NNC3=O Chemical compound NC1(CCC1)c(cc1)ccc1-c(c(-c1ccccc1)c1)nc(C=CN23)c1C2=NNC3=O ULDXWLCXEDXJGE-UHFFFAOYSA-N 0.000 description 1
- GAMHLKCZDZGCFT-NHUVNFLLSA-N Oc1cc(O)c(CC(CC(c(cc2O)cc(O)c2O)=O)[C@@H](c(cc2O)cc(O)c2O)O2)c2c1 Chemical compound Oc1cc(O)c(CC(CC(c(cc2O)cc(O)c2O)=O)[C@@H](c(cc2O)cc(O)c2O)O2)c2c1 GAMHLKCZDZGCFT-NHUVNFLLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161431508P | 2011-01-11 | 2011-01-11 | |
| US61/431,508 | 2011-01-11 | ||
| PCT/US2012/020863 WO2012097021A1 (en) | 2011-01-11 | 2012-01-11 | Combination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103298345A CN103298345A (zh) | 2013-09-11 |
| CN103298345B true CN103298345B (zh) | 2016-12-14 |
Family
ID=46507420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280004830.0A Active CN103298345B (zh) | 2011-01-11 | 2012-01-11 | 组合 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US20130288984A1 (enExample) |
| EP (1) | EP2663189B1 (enExample) |
| JP (1) | JP6100700B2 (enExample) |
| KR (1) | KR20140053836A (enExample) |
| CN (1) | CN103298345B (enExample) |
| AU (1) | AU2012205601B2 (enExample) |
| BR (1) | BR112013017722A2 (enExample) |
| CA (1) | CA2824201A1 (enExample) |
| EA (1) | EA029000B1 (enExample) |
| ES (1) | ES2689760T3 (enExample) |
| IL (1) | IL227097B (enExample) |
| MX (1) | MX356704B (enExample) |
| SG (2) | SG10201600077RA (enExample) |
| WO (1) | WO2012097021A1 (enExample) |
| ZA (1) | ZA201304139B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016004267A (es) * | 2013-10-01 | 2016-07-08 | Novartis Ag | Combinacion. |
| CA2929715A1 (en) * | 2013-11-07 | 2015-05-14 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie2 kinase useful in the treatment of cancer |
| SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
| EA202091763A1 (ru) | 2018-01-31 | 2020-12-14 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Комбинированная терапия для лечения мастоцитоза |
| EP3938363A1 (en) | 2019-03-11 | 2022-01-19 | Teva Pharmaceuticals International GmbH | Solid state forms of ripretinib |
| JP7818502B2 (ja) | 2019-08-12 | 2026-02-20 | デシフェラ・ファーマシューティカルズ，エルエルシー | 胃腸間質腫瘍を治療するためのリプレチニブ |
| WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| SI4084778T1 (sl) | 2019-12-30 | 2024-01-31 | Deciphera Pharmaceuticals, Llc | Formulacije inhibitorja amorfne kinaze in načini njihove uporabe |
| AU2020417282B2 (en) | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6328590B1 (en) | 2000-07-20 | 2001-12-11 | Emc Corporation | Methods and apparatus for controlling attachment of an electronic module with a circuit board connector |
| ES2551293T3 (es) * | 2004-03-24 | 2015-11-17 | Abbvie Inc. | Inhibidores de quinasas de pirazol tricíclicos |
| WO2006040649A1 (en) | 2004-10-13 | 2006-04-20 | Pharmacia & Upjohn Company Llc | Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| JP2009506069A (ja) * | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP1840114A1 (en) | 2006-03-30 | 2007-10-03 | LTB4 Sweden AB | Crystalline Leukotriene B4 |
| EP2004165A2 (en) | 2006-04-05 | 2008-12-24 | Novartis Pharma AG | Synergistic combinations of anticancer agents for treating cancer |
| WO2007122686A1 (ja) | 2006-04-14 | 2007-11-01 | Eisai R & D Management Co., Ltd. | ベンズイミダゾール化合物 |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| HRP20130961T1 (hr) | 2006-08-25 | 2013-11-22 | Janssen Oncology, Inc. | Kombinacije za tretman raka |
| JP4299327B2 (ja) | 2006-08-31 | 2009-07-22 | トヨタ自動車株式会社 | 可変バルブタイミング装置 |
| US8828451B2 (en) | 2006-10-04 | 2014-09-09 | University Of South Florida | Akt sensitization of cancer cells |
| US8357695B2 (en) | 2006-10-13 | 2013-01-22 | Basf Se | Hydrates of 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)-pyrimidinyl]-4-fluoro-N-[[methyl(1-methylethyl)amino]sulfonyl]benzamide |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| AU2008309383B2 (en) | 2007-10-11 | 2012-04-19 | Astrazeneca Ab | Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors |
| WO2009067453A1 (en) * | 2007-11-19 | 2009-05-28 | Syndax Pharmaceuticals, Inc. | Combinations of hdac inhibitors and proteasome inhibitors |
| DE102008044901A1 (de) | 2008-08-29 | 2010-03-04 | Siemens Aktiengesellschaft | Verfahren und Vorrichtung zur Auswahl eines Bestrahlungsplans sowie Bestrahlungsanlage |
| MY161598A (en) | 2009-01-30 | 2017-04-28 | Glaxosmithkline Llc | Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| UY32730A (es) | 2009-06-26 | 2011-01-31 | Novartis Ag | Inhibidores de cyp17 |
| WO2011044415A1 (en) | 2009-10-08 | 2011-04-14 | Glaxosmithkline Llc | Combination |
| CN103841975A (zh) | 2011-04-01 | 2014-06-04 | 基因泰克公司 | Akt抑制剂化合物和厄洛替尼的组合以及使用方法 |
| AU2012250650A1 (en) | 2011-05-03 | 2013-11-14 | University Of Rochester | Methods for treating prostate cancer |
| BR112014000653A2 (pt) | 2011-07-13 | 2017-02-14 | Pharmacyclics Inc | inibidores de tirosina quinase de bruton |
| WO2013053691A1 (en) | 2011-10-10 | 2013-04-18 | Zach System | Process for preparing 17-substituted steroids |
| CA2856646C (en) | 2011-11-30 | 2020-01-14 | Astrazeneca Ab | Combination treatment of cancer |
| EA201492082A1 (ru) | 2012-06-04 | 2015-03-31 | Фармасайкликс, Инк. | Кристаллические формы ингибитора тирозинкиназы брутона |
| US20160235714A1 (en) | 2013-10-01 | 2016-08-18 | Novartis Ag | Enzalutamide in combination with afuresertib for the treatment of cancer |
-
2012
- 2012-01-11 AU AU2012205601A patent/AU2012205601B2/en not_active Ceased
- 2012-01-11 US US13/978,765 patent/US20130288984A1/en not_active Abandoned
- 2012-01-11 BR BR112013017722A patent/BR112013017722A2/pt not_active IP Right Cessation
- 2012-01-11 MX MX2013008074A patent/MX356704B/es active IP Right Grant
- 2012-01-11 EP EP12733916.6A patent/EP2663189B1/en active Active
- 2012-01-11 CA CA2824201A patent/CA2824201A1/en not_active Abandoned
- 2012-01-11 WO PCT/US2012/020863 patent/WO2012097021A1/en not_active Ceased
- 2012-01-11 ES ES12733916.6T patent/ES2689760T3/es active Active
- 2012-01-11 CN CN201280004830.0A patent/CN103298345B/zh active Active
- 2012-01-11 SG SG10201600077RA patent/SG10201600077RA/en unknown
- 2012-01-11 JP JP2013549503A patent/JP6100700B2/ja active Active
- 2012-01-11 KR KR1020137021098A patent/KR20140053836A/ko not_active Abandoned
- 2012-01-11 EA EA201391027A patent/EA029000B1/ru not_active IP Right Cessation
- 2012-01-11 SG SG2013043856A patent/SG191724A1/en unknown
- 2012-02-08 US US13/368,434 patent/US20120258933A1/en not_active Abandoned
-
2013
- 2013-06-06 ZA ZA2013/04139A patent/ZA201304139B/en unknown
- 2013-06-20 IL IL227097A patent/IL227097B/en active IP Right Grant
-
2015
- 2015-01-06 US US14/590,143 patent/US20150119337A1/en not_active Abandoned
- 2015-08-20 US US14/831,261 patent/US20160022641A1/en not_active Abandoned
-
2016
- 2016-09-08 US US15/259,694 patent/US20160375086A1/en not_active Abandoned
- 2016-12-20 US US15/385,205 patent/US10449226B2/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 《Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenibexhibits strong antiproliferative action in human cholangiocarcinoma》;antoni castells;《world journal of gastroenterology》;20070907;第13卷(第33期);第4413-4536页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103298345A (zh) | 2013-09-11 |
| JP6100700B2 (ja) | 2017-03-22 |
| US20150119337A1 (en) | 2015-04-30 |
| US20160375086A1 (en) | 2016-12-29 |
| ES2689760T3 (es) | 2018-11-15 |
| EP2663189B1 (en) | 2018-07-04 |
| AU2012205601B2 (en) | 2016-03-24 |
| US10449226B2 (en) | 2019-10-22 |
| SG191724A1 (en) | 2013-08-30 |
| US20120258933A1 (en) | 2012-10-11 |
| IL227097B (en) | 2018-02-28 |
| MX2013008074A (es) | 2013-08-09 |
| CA2824201A1 (en) | 2012-07-19 |
| EA029000B1 (ru) | 2018-01-31 |
| AU2012205601A1 (en) | 2013-08-01 |
| SG10201600077RA (en) | 2016-02-26 |
| MX356704B (es) | 2018-06-11 |
| EP2663189A4 (en) | 2014-06-11 |
| EP2663189A1 (en) | 2013-11-20 |
| US20160022641A1 (en) | 2016-01-28 |
| BR112013017722A2 (pt) | 2016-07-12 |
| US20170100449A1 (en) | 2017-04-13 |
| WO2012097021A1 (en) | 2012-07-19 |
| KR20140053836A (ko) | 2014-05-08 |
| ZA201304139B (en) | 2014-02-26 |
| EA201391027A1 (ru) | 2014-01-30 |
| JP2014507412A (ja) | 2014-03-27 |
| US20130288984A1 (en) | 2013-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103298345B (zh) | 组合 | |
| EP2572199B1 (en) | Combination | |
| AU2010303363B2 (en) | Combination | |
| AU2010303364B2 (en) | Combination | |
| US20150094283A1 (en) | Combination | |
| US20150272950A1 (en) | Combination | |
| AU2013334943A1 (en) | Combination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151022 Address after: Basel, Switzerland Applicant after: NOVARTIS AG Address before: Basel, Switzerland Applicant before: NOVA LABORATORIES SDN BHD Effective date of registration: 20151022 Address after: Basel, Switzerland Applicant after: NOVA LABORATORIES SDN BHD Address before: American Pennsylvania Applicant before: GLAXOSMITHKLINE LLC |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |